Tenax Therapeutics regains Nasdaq minimum float compliance; deficiency closed

TENAX THERAPEUTICS, INC.

Received Nasdaq notice on Feb 22, 2024 confirming over 500,000 publicly held shares.
Regained compliance with Nasdaq Listing Rule 5550(a)(4) regarding minimum public float.
Prior deficiency notice on Jan 11, 2024 has been resolved and matter closed.
Company remains listed on Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.